Global Search | Novartis

Hide Filters

Sort by

Relevance

Newest first

Oldest first

Showing 2660 results

Event calendar
Event / Oct 07, 2024
Novartis Financial Results – Q2 2023
Novartis announced the company’s financial results for the second quarter and first half of 2023.
Clinical Trials / Nov 19, 2024
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
Clinical Trials / Nov 19, 2024
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
Clinical Trials / Nov 19, 2024
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
Clinical Trials / Nov 19, 2024
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
Clinical Trials / Nov 19, 2024
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
Clinical Trials / Nov 15, 2024
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Clinical Trials / Nov 14, 2024
An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).
Clinical Trials / Nov 13, 2024
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)